Upadacitinib Effective in Adolescents With AD Through 76 Weeks

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology.

“Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks” used data from three large, global phase 3 randomized clinical trials—the ongoing Measure Up 1, Measure Up 2, and AD Up trials—including 542 adolescents. Once-daily upadacitinib (15 mg or 30 mg) with or without topical corticosteroids was found to be effective in treating moderate to severe atopic dermatitis, with responses maintained through 76 weeks of treatment. No new risks were observed.

At Week 76, at least 84.4% of adolescent patients taking upadacitinib in each trial achieved EASI-75, among other results.

“These results through 76 weeks demonstrated that upadacitinib, with a favorable benefit-risk profile, was an effective long-term treatment option for adolescents with moderate to severe AD,” the authors wrote.